1. Home
  2. ECO vs ADPT Comparison

ECO vs ADPT Comparison

Compare ECO & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Okeanis Eco Tankers Corp.

ECO

Okeanis Eco Tankers Corp.

HOLD

Current Price

$55.45

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.68

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECO
ADPT
Founded
2018
2009
Country
Greece
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.3B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
ECO
ADPT
Price
$55.45
$14.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$42.00
$17.78
AVG Volume (30 Days)
359.3K
1.4M
Earning Date
05-13-2026
05-05-2026
Dividend Yield
6.12%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
$16.07
$3.98
Revenue Next Year
N/A
$22.72
P/E Ratio
$18.60
N/A
Revenue Growth
N/A
54.77
52 Week Low
$21.27
$8.38
52 Week High
$57.29
$20.76

Technical Indicators

Market Signals
Indicator
ECO
ADPT
Relative Strength Index (RSI) 64.52 54.83
Support Level $48.57 $12.22
Resistance Level $57.29 $15.38
Average True Range (ATR) 2.07 0.61
MACD 0.32 0.06
Stochastic Oscillator 83.98 76.94

Price Performance

Historical Comparison
ECO
ADPT

About ECO Okeanis Eco Tankers Corp.

Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: